News
DNA
8.24
+1.48%
0.12
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
Benzinga · 12h ago
Weekly Report: what happened at DNA last week (0407-0411)?
Weekly Report · 12h ago
AI-focused drug discovery firms rise as FDA phases out animal testing
Seeking Alpha · 3d ago
Buy Certara After The FDA Announcement
Seeking Alpha · 3d ago
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Benzinga · 3d ago
Ginkgo Bioworks, partners awarded $29M contract by ARPA-H
TipRanks · 4d ago
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain
PR Newswire · 4d ago
Largest borrow rate increases among liquid names
TipRanks · 04/07 12:45
Weekly Report: what happened at DNA last week (0331-0404)?
Weekly Report · 04/07 09:10
Ginkgo Bioworks falls -4.8%
TipRanks · 04/02 13:50
Weekly Report: what happened at DNA last week (0324-0328)?
Weekly Report · 03/31 09:11
Largest borrow rate increases among liquid names
TipRanks · 03/24 12:45
Weekly Report: what happened at DNA last week (0317-0321)?
Weekly Report · 03/24 09:10
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
NASDAQ · 03/21 22:15
Weekly Report: what happened at DNA last week (0310-0314)?
Weekly Report · 03/17 09:11
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
NASDAQ · 03/14 13:35
Weekly Report: what happened at DNA last week (0303-0307)?
Weekly Report · 03/10 09:11
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
NASDAQ · 03/05 17:00
Weekly Report: what happened at DNA last week (0224-0228)?
Weekly Report · 03/03 09:11
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat
Simply Wall St · 03/01 12:53
More
Webull provides a variety of real-time DNA stock news. You can receive the latest news about Ginkgo Bioworks Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About DNA
More
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.